SCHEMBL648210

SCHEMBL648210

CCc1ccc(N)c(C(=O)O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.72
CDC25B P30305 1/20 0.72
CASP6 P55212 1/20 0.72
RCE1 Q9Y256 1/20 0.72
KDM4E B2RXH2 3/20 0.57
KMT2A Q03164 2/20 0.57
GFER P55789 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
MAPT P10636 2/20 0.55
MCL1 Q07820 2/20 0.55
MEN1 O00255 1/20 0.55
USP2 O75604 1/20 0.55
POLB P06746 1/20 0.55
THRB P10828 1/20 0.55
PKM P14618 1/20 0.55
APEX1 P27695 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7018271 0.85 ALDH1A1 (0.68) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL1685286 0.85 ALDH1A1 (0.52) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL4097033 0.85 ALDH1A1 (0.54) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL20670595 0.85 ALDH1A1 (0.54) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL25170829 0.84 ALDH1A1 (0.78) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL30291197 0.84 ALDH1A1 (0.78) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL29861837 0.84 ALDH1A1 (1.00) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL107442 0.84 ALDH1A1 (1.00) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL29832194 0.84 ALDH1A1 (1.00) ALDH1A1CDC25BCASP6RCE1KDM4E
SCHEMBL9041416 0.83 ALDH1A1 (0.53) ALDH1A1CDC25BCASP6RCE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 CN disclosed
CN-118176259-A Dispersion of carbon nanotubes, coating liquid composition for electrode using same, electrode, and lithium ion secondary battery 第一工业制药株式会社 2024-06-11 CN disclosed
CN-118043733-A Polymer dispersed liquid crystal element and method for manufacturing same 日产化学株式会社 2024-05-14 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
CN-111690321-B Varnish for photo-alignment film and liquid crystal display device 株式会社日本显示器 2022-02-08 CN disclosed
CN-111690321-A Varnish for photo-alignment film and liquid crystal display device 株式会社日本显示器 2020-09-22 CN disclosed
US-20190300509-A1 MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE "AMEDEO AVOGADRO" (IT) 2019-10-03 US disclosed
US-6291523-B1 SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS NOVARTIS AG (CH) 2001-09-18 US disclosed
CN-1268112-A Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives thereof NOVARTIS AG (CH) 2000-09-27 CN disclosed
EP-1007505-A1 CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES Novartis AG (CH) 2000-06-14 EP disclosed
WO-1999011605-A1 CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES NOVARTIS AG (CH) 1999-03-11 WO disclosed
US-4673631-A OF AN AMINO ACID COMPOUND CANON KABUSHIKI KAISHA (JP) 1987-06-16 US disclosed
US-4543356-A Quinazoline derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-09-24 US disclosed
EP-0030156-B1 QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-03-21 EP disclosed
US-4429126-A ANTIASTHMA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-01-31 US disclosed
US-4377580-A ANTIALLERGENIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-03-22 US disclosed
EP-0030156-A1 Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300509-A1 MODULATORS OF SOCE, COMPOSITIONS, AND USES THEREOF STIM1, ORAI1, SARAF ALDH1A1 1839/4885CDC25B 802/4885CASP6 2179/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT ALDH1A1 2733/4885CDC25B 2661/4885CASP6 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.